Why Is GSK Stock Gaining Monday?
GSK shares jump over 4% on strong survival data for SCLC drug Ris-Rez and a 94% response rate for Jideytro in NSCLC.
Share
Why It Matters
GSK's cancer medicines showed strong test results. This hints the company's drugs might help more patients than expected.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.